Resources / Pharmaceutical Alternative Distribution Models: How Manufacturers are Creating Savings and Enhancing Transparency Through Direct Distribution
Pharmaceutical Alternative Distribution Models: How Manufacturers
are Creating Savings and Enhancing Transparency Through Direct
Distribution
Adam Keeth, Vice President of Sales and Strategic Accounts
The pharmaceutical distribution model has remained largely unchanged
since the 1960s. There are an increasing amount of new product types and new
regulations to meet. Yes, the traditional model has made some changes, but it
still lags behind the evolution of the pharmaceutical environment over the last
decade. Wholesalers have consolidated into a few mega brands. However, the basic
distribution model remains the same: the manufacturer sells to the wholesaler, the
wholesaler sells to the provider or pharmacy, then the wholesaler sends a
chargeback or cash request to the manufacturer. This has been the distribution
process used for over 60 years. While the traditional business model is still
effective, it lacks transparency and offers only limited flexibility to
manufacturers, especially as channel costs continue to rise. An increase in
Wholesale Acquisition Costs (WAC) means higher distribution costs, even if unit
sales remain constant. Any product with requirements incur higher costs and manual
workarounds, as additional efforts are needed to capture and process the data
necessary to complete the distribution process. Simply, the current distribution
model needs to further evolve to become more efficient and transparent to address
contemporary challenges for products, patients, and regulations.
With traditional wholesalers maintaining stagnant practices,
manufacturers’ interest in new distribution models continue to grow. Wholesaler
fees erode the ability to lower cost to patients and limit the ability to invest
in growth strategies that directly benefit the business. As manufacturers grapple
with these financial constraints, it becomes clear that a new approach is
needed—one that prioritizes customer service and cost savings without compromising
the operational efficiency of the current model.
For example, the growth of 340B and the implications for Maximum Fair
Price, as required under the IRA, bring new challenges that are not easily
addressed in the current distribution model. Lilly launched a direct-to-patient
model, “Lilly Direct,” in an effort to improve efficiency and patient adherence
with lower channel costs for their GLP-1 products. Pfizer has launched a
direct-to-patient model for their oral COVID products and migraine nasal spray.
Other manufacturers have adopted direct-to-provider or pharmacy models as well in
an effort to control where their product is shipped and gather necessary data, all
at a lower cost than the aforementioned traditional model. As of today, there are
no clear answers on how Maximum Fair Price or 340B distribution will work and it
is hard to make a case for traditional distribution practices to continue.
So, the question remains: How do I, as a manufacturer, change my
distribution model without compromising service and care?
What if that solution already exists and has been adopted by other
peer organizations?
DCS’ partner manufacturers have embraced our unique distribution
model, resulting in them taking control of their supply chain. They have gained
access to the following operational capabilities without having to build
internally, all while incorporating into current operations and launch plans. Our
solution immediately provides you:
I’ve found that the manufacturers who have engaged with Direct
Distribution strategies have embraced and integrated the following benefits into
their organizational work flows and business planning:
1. Controlled, Precise Distribution
Manufacturers often find themselves locked into existing and
increasingly expensive distribution models that lack the flexibility required to
enhance efficiency, provide visibility, and reduce risks on a product-by-product
basis. The increasing demand for “just in time” inventory at traditional
distribution outlets coupled with the expectation of expedient delivery of
therapies to patients shouldn’t mean resorting to the way we have always done
things. When streamlined, an optimized Direct Distribution model can provide the
following benefits:
- Reduce product locations to simplify the processing of orders and reduce inventory on hold.
- Use live inventory and order data to plan business operations and forecast accurately.
- Deliver medication to the correct customer and location at the correct contract price.
- Ensure temperature control throughout the journey.
- Check licensing and all eligibility requirements in a compliant and timely manner.
- Improve product allocation and visibility of all pertinent customer data.
2. Reduction in Distribution Costs
The distribution fees on many medications today are higher than the
actual cost of the drug. Direct Distribution allows manufacturers to lower costs
and increase cash flow. When a shift is made to a direct model, manufacturers
see meaningful improvement to their balance sheet immediately. These funds are
retained by manufacturers instead of being sent to third-party wholesalers. This
savings allows manufacturers to increase services to pharmacies, improve
accessibility for patients, and boost R&D expenditures.
In a direct title model, the product is never transferred to the
intermediary and is only transferred when it reaches the end customer. This
nuance allows for a per unit fee per NDC at a single negotiated cost that is not
connected to WAC or contract price. The other inherent advantage to this model
is elimination of chargebacks. Manufacturers bill at specific contract cost and
are no longer bound to the credit/debit balance accounts at wholesalers.
Overall, a cost-effective distribution system benefits both
healthcare providers and manufacturers, creating a more effective and affordable
healthcare ecosystem. By reducing intermediary costs, it extends the product
lifecycle and prevents drugs from being removed from the market.
3. Transparent Data and Financial Services
In today’s sales environment, data is invaluable. In the standard
model, where manufacturers rely on the traditional wholesalers, they lose
visibility into where their products are located and which customers are
purchasing. Without full visibility, how can manufacturers effectively
strategize and prepare? For example, at DCS, manufacturers have access to all
their crucial data. This allows for precise shaping of commercial strategy in
ways that most manufacturers have not been able to before. By building direct
relationships with end customers, manufacturers can regain control over their
brand and customer experience by receiving inventory, shipping, and invoice
details in real time. Even more importantly, having access to that data empowers
manufacturers to make informed decisions on allocations and contracts. A
comprehensive, full-service business intelligence platform enables manufacturers
to make the leap to Direct Distribution—eliminating the need for intermediaries
like wholesalers, specialty distributors, and other middle players in the supply
chain.
So, the question remains: How do I, as a manufacturer, change my
distribution model without compromising service and care?
Why DCS?
The DCS Direct Distribution model can deliver financial stability
and control for manufacturers. However, for a manufacturer to transition to this
model, it must prove that the new system is financially advantageous for the
organization. The process of building a warehouse and the necessary
infrastructure is often a significant barrier for most bio-pharma companies.
That’s where DCS comes in as your white-label solution for distribution.
How do you use our roadmap to solve the aforementioned
concerns?
We set up secure order processing and invoicing in collaboration
with our financial services team, ensuring that products are shipped on time and
to the correct location. To minimize customer disruption, our national sales
team helps ensure smooth sign-ups and alignment to your organization’s
contractual requirements. Our fees, based on a per-item rate, maximize savings
and operational efficiencies for each client, while also providing you with
real-time data and brand promotion that a traditional model is incapable of
offering.
Through simple discussions, DCS can scope direct distribution fees
against your current distribution model. The unit fee covers pick/pack/ship,
freight, AR functions, quality checks, DSCSA compliance, and data reporting. The
program yields reduced costs, improved cash flow, and deeper insights to drive
projection efficiency. With fully integrated channel services, manufacturers can
develop more effective sales and distribution strategies aligned with their
commercial goals.
DCS recently onboarded a pharmaceutical manufacturer for exclusive
340B sales through distribution of three newly acquired branded oral oncology
products. The company was able to utilize our automated warehouse, carrier
contracts, customer service, and national sales team, along with financial
services, to fulfill its obligations under the 340B program. In the first two
quarters of the program, our partner was able to capture a 50% reduction in
wholesaler service fees and achieved a 100% reduction in chargeback liability by
going direct. This is only one example.
This solution is available to you as well.
How is Direct Distribution my solution?
In summary, Direct Distribution is a vital option manufacturers can
leverage to solve challenges, enhance their overall market access, and solidify
distribution operations.
As the number of new products with unique characteristics continues to
grow, along with the sustained growth of the 340B program and increasing
manufacturer restrictions, traditional distribution faces significant challenges
in meeting the ever-evolving needs of the pharmaceutical industry. Furthermore,
the IRA presents several new obstacles for manufacturers (and providers) that
outdated distribution processes fail to resolve. Specialty and rare products often
require limited distribution, data, and adherence services along with more
favorable channel cost structures to improve their gross-to-net. Manufacturers
require inventory transparency, full access to sales data, and significant
distribution savings, including improved cash flow for sustainability and/or
growth. DCS provides turnkey solutions that provide flexibility and meet the needs
of the modern pharmaceutical manufacturer.
About DCS
DCS is revolutionizing pharmaceutical logistics by providing
manufacturers with innovative distribution alternatives. We deliver exceptional
service with integrity, transparent communication, and world-class capabilities,
offering our partners superior value over the competition.
Contact Us:
traderelations@directcustomersolutions.com
731.694.7729